BC Innovations | Jan 19, 2017
Translation in Brief

Pockets against pain

Amgen Inc. (NASDAQ:AMGN) is aiming to tackle neuropathic pain by boosting glycine receptor α 3 ( GLRA3 ) activity in the CNS. In a December study, the company presented preclinical data and crystal structures for its GLRA3...
BC Innovations | Jan 18, 2017
Distillery Therapeutics


INDICATION: Pain Cell culture and mouse studies identified a positive allosteric modulator (PAM) of GLRA3 that could help treat neuropathic pain. High throughput screening and chemical synthesis to optimize hits yielded a tricyclic sulfonamide-based GLRA3...
BC Innovations | Feb 13, 2014
Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Mouse models of epilepsy and anxiety A study in mice suggests neuron type-specific perturbation of glycine receptor α3 (GLRA3) could help...
BC Innovations | Oct 28, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Apnea Glycine receptor a3 (GLRA3); serotonin (5-HT1A) receptor Studies in mice suggest that activation of 5-HT1A receptors could help prevent opioid- and disease-associated apneas. In...
Items per page:
1 - 4 of 4